The International Association for the Study of Lung Cancer (IASLC) highlighted the ten most-cited articles from the Journal of Thoracic Oncology on LinkedIn, noting that they reflect the depth, rigor and global impact of research in thoracic oncology and thanking the authors, reviewers and readers who contribute to the journal.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial — Five-year overall survival data assessing durvalumab-based immunotherapy combinations in first-line metastatic non–small cell lung cancer (NSCLC).
High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study — Prospective real-world evaluation of high-dose furmonertinib for EGFR-mutant NSCLC with leptomeningeal involvement.
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03 — Phase 2 results examining sacituzumab govitecan as second-line treatment for extensive-stage small-cell lung cancer (SCLC).
Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial — Supplementary analysis identifying factors associated with locoregional relapse following segmentectomy for early-stage lung cancer.
Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the IASLC Pathology Committee — Consensus recommendations on distinguishing separate primary lung adenocarcinomas from intrapulmonary metastases using pathological and molecular criteria.
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC — Randomized phase II trial investigating maintenance atezolizumab with or without talazoparib in SLFN11-positive extensive-stage SCLC.
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis — Meta-analysis showing improved event-free survival when complete or major pathologic responses follow neoadjuvant chemoimmunotherapy in resectable NSCLC.
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report — Final overall survival and long-term safety outcomes for lorlatinib in ALK-positive NSCLC from a pivotal phase 2 study.
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A — Results evaluating the combination of amivantamab and lazertinib in EGFR-mutant NSCLC after progression on osimertinib and platinum chemotherapy.
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA) — Trial results on the use of osimertinib in neoadjuvant and adjuvant settings for stage IA–IIIA EGFR-mutant NSCLC.
The list highlights influential work across immunotherapy, targeted therapy, surgery and pathology that is shaping clinical practice and research priorities in thoracic oncology.
Leave a Reply